Unicycive Therapeutics (UNCY) Enterprise Value (2021 - 2026)

Unicycive Therapeutics (UNCY) has reported Enterprise Value for 6 consecutive years, with $69.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 53.86% year-over-year to $69.2 million; the trailing twelve-month figure through Jun 2026 stood at $69.2 million (up 53.86% YoY), and the FY2025 full-year result was $50.4 million, up 86.26% from the prior year.
• Enterprise Value declined to $69.2 million in Q2 2026 per UNCY's latest filing, from $111.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at $111.5 million in Q1 2026 and bottomed at -$19.9 million in Q2 2024.
• Historically, Enterprise Value has averaged $24.7 million across 5 years, with a median of $9.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 3015.55% in 2024, then jumped 1553.95% in 2025.
• Over 5 years, Enterprise Value stood at $7.8 million in 2022, then jumped by 49.18% to $11.6 million in 2023, then soared by 133.42% to $27.1 million in 2024, then jumped by 86.26% to $50.4 million in 2025, then surged by 37.34% to $69.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $69.2 million, $111.5 million, and $50.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.